Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	2.35B
Revenue (ttm)	878.05M
Net Income (ttm)	97.02M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	24.26
Forward PE	16.55
Dividend	0.02 (2.19%)
Ex-Dividend Date	Jun 18, 2025

Volume	n/a
Average Volume	61
Open	0.9550
Previous Close	0.9500
Day's Range	0.9550 - 0.9550
52-Week Range	0.5850 - 1.0200
Beta	n/a
RSI	50.13
Earnings Date	May 8, 2025

About FRA:S2P

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY